Featured Story | Thursday, June 11, 2020 Gilead Sciences perhaps faces the toughest decision in the entire biopharma industry on the pricing of COVID-19 drug remdesivir. Now, one Wall Street analyst is voicing his support for Gilead, arguing the Big Biotech shouldn’t be pressured to price remdesivir too low or penalized for making a sizable profit along the way. read more |
| |
|---|
|
Top Stories Thursday, June 11, 2020 Insurers should brace for volatility in the individual market as major job losses due to COVID-19 could increase morbidity in the marketplace, a study found. read more Thursday, June 11, 2020 With much of the world caught up in responding to COVID-19, experts and lawmakers are again underscoring the need to prepare for the next pandemic, as distant a concern as it may seem. read more Tuesday, June 9, 2020 As the industry braces for the next phase of COVID-19, experts at Kaiser Permanente are sharing several key capabilities that will be critical to prepare for another potential surge. read more Thursday, June 11, 2020 Moderna has finalized the design and dosage of its phase 3 COVID-19 vaccine trial, keeping it on track to start the pivotal test next month. Work to get the 30,000-subject phase 3 trial underway is advancing in parallel to ongoing enrollment in earlier phases of development. read more Thursday, June 11, 2020 As state and local officials look to reopen schools in the fall, pediatricians and primary care doctors will likely field a lot of questions from worried parents about whether it's safe to send their children back to classrooms amid the coronavirus. Here's what physicians need to know, according to public health and education experts. read more Thursday, June 11, 2020 Moderna and Merck execs warned that sourcing ingredients and finding enough staff could stall vaccine development, while Pfizer said it hadn't considered the ROI for its shot yet. Analysts pushed Gilead to monetize remdesivir, with one Wall Street analyst's support. And Sinopharm's COVID-19 vaccine cleared animal trials. read more Wednesday, June 10, 2020 An annual survey of pharma sales rep salaries showed another year-over-year increase, but it also revealed concerns about the impact of the COVID-19 pandemic. Salaries averaged more than $150,000 in 2019, for an increase of 6%. However, three-fourths of the pharma sales reps interviewed said they expect the COVID-19 crisis to negatively impact their incomes this year. read more Thursday, June 11, 2020 Geisinger Health System is harnessing its online patient portal to monitor COVID-19 patients from home. read more Thursday, June 11, 2020 AstraZeneca made waves last week when it signed a massive $750 million deal to ramp production of a University of Oxford COVID-19 vaccine up to 2 billion doses per year. Now, as part of a Trump administration effort to get shots into U.S. hands as soon as possible, AstraZeneca has agreed to another major manufacturing tie-up. read more Tuesday, June 9, 2020 A group of healthcare leaders from health data platform Innovaccer launched a new virtual community for doctors this week. Called CareAsOne, the platform is aimed at providing a credible place for industry professionals to connect and share news and information around healthcare transformation and patient-centered care. read more |
|
